A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients

NCT01628965 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

143

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson's Disease

Interventions

DRUG: SPM 962

Sponsor

Otsuka Pharmaceutical Co., Ltd.